лечение с Trudexa отговориха до седмица 12 в сравнение с 30% от пациентите на поддържаща терапия с плацебо.
Among patients who were not in response at week 4, 43% of Trudexa maintenance patients responded by week 12 compared to 30% of placebo maintenance patients.